Improving the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma by Repurposing Disulfiram

BackgroundSorafenib, a kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC) but provides only a limited survival benefit. Disulfiram (DSF), a drug for treating alcoholism and a chelator of copper (Cu), forms a complex with Cu (DSF/Cu). DSF/Cu is a potent inducer of a...

Descripción completa

Detalles Bibliográficos

Autores principales:	Gong Zhang, Yufeng Wang, Bryan C. Fuchs, Wei Guo, David L. Drum, Derek J. Erstad, Baomin Shi, Albert B. DeLeo, Hui Zheng, Lei Cai, Liyuan Zhang, Kenneth K. Tanabe, Xinhui Wang
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Frontiers Media S.A. 2022-07-01
Colección:	Frontiers in Oncology
Materias:	sorafenib disulfiram copper hepatic cancer stem cells ERK pathway
Acceso en línea:	https://www.frontiersin.org/articles/10.3389/fonc.2022.913736/full
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!